STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.